JP MORGAN/CALL/BECTON DICKINSON AND CO./275/0.1/21.06.24 Stock

Warrant

DE000JB03XT0

Real-time Bid/Ask 10:08:54 2024-05-21 am EDT
0.01 EUR / 0.11 EUR +566.67% Intraday chart for JP MORGAN/CALL/BECTON DICKINSON AND CO./275/0.1/21.06.24
Current month-89.29%
1 month-90.22%
Date Price Change
24-05-21 0.008 -11.11%
24-05-20 0.009 -35.71%
24-05-17 0.014 -30.00%
24-05-16 0.02 +5.26%
24-05-15 0.019 -20.83%

Delayed Quote Börse Stuttgart

Last update May 21, 2024 at 02:38 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer J.P. Morgan
WKN JB03XT
ISINDE000JB03XT0
Date issued 2023-08-22
Strike 275 $
Maturity 2024-06-21 (31 Days)
Parity 10 : 1
Emission price 2.44
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 4.03
Lowest since issue 0.008
Spread 0.501
Spread %98.24%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
237.1 USD
Average target price
279 USD
Spread / Average Target
+17.66%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW